Clinical Trial Update: Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function [Phase 1]

View source ↗

Summary

Phase 1 study investigating the effects of eslicarbazepine acetate (BIA 2-093) on cognition and psychomotor function in epilepsy patients; results were posted a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• eslicarbazepine acetate (eslicarbazepine acetate)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Epilepsy | Phase 1 | Status: COMPLETED | Results posted: 2014-12-10